Next 10 |
home / stock / alpmf / alpmf news
2024-05-02 15:32:05 ET Summary CytomX Therapeutics, Inc. results from phase 1a dose-escalation study, using CX-904 for the treatment of patients with EGFR expressing solid tumors, expected with Q1 2024 earnings on May 8, 2024. Pending positive data, plus at the discretion of partn...
2024-05-01 13:54:38 ET Poseida Therapeutics ( NASDAQ: PSTX ) shares traded higher on Wednesday after the company and Japanese drugmaker Astellas ( OTCPK:ALPMY ) announced a partnership to develop and commercialize CAR-T cell therapies for cancer.... Read the full article o...
2024-04-26 18:00:03 ET Astellas Pharma Inc. (ALPMF) Q4 2023 Results Conference Call April 25, 2024 04:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura - President and Chief Executive Office Yoshitsu...
2024-04-25 03:54:46 ET More on Astellas Pharma: Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Astellas collaborates with Mass General Brigham for translational medicine Historical earnings data for Astellas Pharma Read the ...
2024-04-24 11:12:04 ET Major earnings expected before the bell on Thursday include: Bristol-Myers Squibb ( BMY ) Caterpillar ( CAT ) Comcast ( CMCSA ) Altria Group ( MO ) Merck & Co ( MRK ) Read the full article on Seeking Alpha Fo...
2024-04-05 10:56:25 ET More on Ocugen Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues Ocugen slips as accounting errors force restatements Ocugen shares make gains after US court dismisses class action lawsuits Seeking ...
2024-03-28 11:54:15 ET More on Astellas Pharma, Pfizer etc. Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns Pfizer Inc. (PFE) Leerink Partners Global Biopharma Conference 2024 - (Transcript) Pfizer: Seagen Acquisition Starting To Bea...
2024-03-17 00:40:48 ET Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is ...
2024-02-05 13:08:05 ET Astellas Pharma Inc. (ALPMF) Q3 2023 Results Earnings Conference Call February 5, 2024, 02:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Financial Officer Tadaaki Taniguchi...
2024-02-05 08:06:35 ET More on Astellas Pharma Astellas Pharma Inc. 2023 Q3 - Results - Earnings Call Presentation FDA denies approval of Astellas gastric cancer drug Astellas and Elpiscience collaborate for novel bi-specific macrophage engagers Historical ea...
News, Short Squeeze, Breakout and More Instantly...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...